NDC 0069-0342

Zirabev

Bevacizumab-bvzr

Zirabev is a Intravenous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Pfizer Laboratories Div Pfizer Inc. The primary component is Bevacizumab.

• Product ID: 0069-0342_66321ee2-0493-4656-b311-23ec688eb829
• NDC: 0069-0342
• Product Type: Human Prescription Drug
• Proprietary Name: Zirabev
• Generic Name: Bevacizumab-bvzr
• Dosage Form: Injection, Solution
• Route of Administration: INTRAVENOUS
• Marketing Start Date: 2020-01-13
• Marketing Category: BLA / BLA
• Application Number: BLA761099
• Labeler Name: Pfizer Laboratories Div Pfizer Inc
• Substance Name: BEVACIZUMAB
• Active Ingredient Strength: 400 mg/16mL
• Pharm Classes: Vascular Endothelial Growth Factor Inhibitor [EPC],Vascular Endothelial Growth Factor-directed Antibody Interactions [MoA],Vascular Endothelial Growth Factor Inhibitors [MoA]
• NDC Exclude Flag: N
• Listing Certified Through: 2021-12-31

Packaging

NDC 0069-0342-01

1 VIAL, SINGLE-USE in 1 CARTON (0069-0342-01) > 16 mL in 1 VIAL, SINGLE-USE

• Marketing Start Date: 2020-01-13
• NDC Exclude Flag: N
• Sample Package?: N

NDC SPL Data Element Entries

NDC 0069-0342-01 [00069034201]

Zirabev INJECTION, SOLUTION

• Marketing Category: BLA
• Application Number: BLA761099
• Product Type: HUMAN PRESCRIPTION DRUG
• Billing Unit: ML
• Marketing Start Date: 2020-01-13

Drug Details

Active Ingredients

Ingredient	Strength
BEVACIZUMAB	400 mg/16mL

Pharmacological Class

• Vascular Endothelial Growth Factor Inhibitor [EPC]
• Vascular Endothelial Growth Factor-directed Antibody Interactions [MoA]
• Vascular Endothelial Growth Factor Inhibitors [MoA]

NDC Crossover Matching brand name "Zirabev" or generic name "Bevacizumab-bvzr"

NDC	Brand Name	Generic Name
0069-0315	Zirabev	bevacizumab-bvzr
0069-0342	Zirabev	bevacizumab-bvzr